Stock comparison
IRadimed
IRMD$1.18BHealthcare Market cap, Sector
Sanofi Consumer Healthcare India Limited
SANOFICONR.BO$104.05BHealthcare Market cap, Sector
Overall winner
Sanofi Consumer Healthcare India Limited
IRMD 15 SANOFICONR.BO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
IRMD1wins
5winsSANOFICONR.BO
68C
B78
89A
A89
92A
B83
76B
B77
65C
A91
78B
A86
75B
A85
Side-by-side metrics
| Metric | IRMD | SANOFICONR.BO |
|---|---|---|
| Market cap | $1.18B | $104.05B Winner |
| P/E (TTM) | 50.4x | 44.0x Winner |
| EV/EBIT | 43.4x | 31.7x Winner |
| ROIC (TTM) | 21.38% | 59.15% Winner |
| Gross margin | Winner: 76.84% | 68.13% |
| Net margin | Winner: 27.36% | 27.35% |
| Revenue CAGR 5y | 18.99% | 27.01% Winner |
| EPS CAGR 5y | Winner: 23.53% | 20.67% |
| Debt / Equity | Winner: - | 0.1x |
| Dividend yield | 1.33% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IRMD leads on
- Debt / Equity-vs 0.1x+100%
- EPS CAGR 5y23.53%vs 20.67%+12%
- Gross margin76.84%vs 68.13%+11%
SANOFICONR.BO leads on
- Market cap$104.05Bvs $1.18B+99%
- ROIC (TTM)59.15%vs 21.38%+64%
- Revenue CAGR 5y27.01%vs 18.99%+30%
- EV/EBIT31.7xvs 43.4x+27%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.